Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate TG Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding TG Therapeutics, Inc.’s stock price such as:

• TG Therapeutics, Inc.’s current stock price and volume
• Why TG Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TGTX from analysts
• TGTX’s stock price momentum as measured by its relative strength

About TG Therapeutics, Inc. (TGTX)

Before we jump into TG Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Want to learn more about TG Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about TG Therapeutics, Inc..

TG Therapeutics, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, TG Therapeutics, Inc.’s stock price was $33.260.

TG Therapeutics, Inc. is down 0.45% from its previous closing price of $33.410.

During the last market session, TG Therapeutics, Inc.’s stock traded between $32.910 and $33.610. Currently, there are approximately 145.42 million shares outstanding for TG Therapeutics, Inc..

TG Therapeutics, Inc.’s price-earnings (P/E) ratio is currently at 12.0, which is low compared to the Biotechnology industry median of 19.7. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

TG Therapeutics, Inc. Stock Price History

TG Therapeutics, Inc.’s (TGTX) price is currently down 4.37% so far this month.

During the month of November, TG Therapeutics, Inc.’s stock price has reached a high of $36.500 and a low of $29.800.

Over the last year, TG Therapeutics, Inc. has hit prices as high as $46.480 and as low as $25.280. Year to date, TG Therapeutics, Inc.’s stock is up 10.5%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused TG Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there was 1 analyst who downgraded TG Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate TG Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on TG Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

TG Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about TG Therapeutics, Inc. (TGTX) by visiting AAII Stock Evaluator.

Relative Price Strength of TG Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, TG Therapeutics, Inc. has a weighted four-quarter relative price strength of -1.55%, which translates to a Momentum Score of 54 and is considered to be Average.

Want to learn more about how TG Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

TG Therapeutics, Inc. Stock Price: Bottom Line

As of November 28, 2025, TG Therapeutics, Inc.’s stock price is $33.260, which is down 0.45% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like TG Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.